Author name: aclairo2024dev

Uyen Dinh, PhD and I were delighted to be asked to contribute to a special edition of Frontiers in Immunology […]

EPL and Aclairo Pharmaceutical Development Group, Inc. are looking forward to seeing everyone at the SOT 65th Annual Meeting in

FDA has issued a new gene editing guidance that gives additional information on expectations for use of next-generation sequencing. The

Aclairo’s Ron Wange and the HESI Targeted Protein Degrader Safety Group recently published a review of key safety issues with

Jennifer Wheeler, Uyen Dinh, PhD, and Lauren Mihalcik, PhD, DABT will all be in Boston next week for ASGCT. This